B-Cancer	0	7	Ovarian	Ovarian	JJ	B-NP
I-Cancer	8	15	cancers	cancer	NNS	I-NP
O	16	27	overexpress	overexpres	VBP	B-VP
O	28	31	the	the	DT	B-NP
O	32	45	antimicrobial	antimicrobial	JJ	I-NP
O	46	53	protein	protein	NN	I-NP
O	54	58	hCAP	hCAP	NN	I-NP
O	58	59	-	-	HYPH	B-NP
O	59	61	18	18	CD	I-NP
O	62	65	and	and	CC	O
O	66	69	its	its	PRP$	B-NP
O	70	80	derivative	derivative	JJ	I-NP
O	81	83	LL	LL	NN	I-NP
O	83	84	-	-	HYPH	O
O	84	86	37	37	CD	B-NP
O	87	96	increases	increase	VBZ	B-VP
B-Cell	97	104	ovarian	ovarian	JJ	B-NP
I-Cell	105	111	cancer	cancer	NN	I-NP
I-Cell	112	116	cell	cell	NN	I-NP
O	117	130	proliferation	proliferation	NN	I-NP
O	131	134	and	and	CC	I-NP
O	135	143	invasion	invasion	NN	I-NP
O	143	144	.	.	.	O

O	145	148	The	The	DT	B-NP
O	149	153	role	role	NN	I-NP
O	154	156	of	of	IN	B-PP
O	157	160	the	the	DT	B-NP
O	161	164	pro	pro	AFX	I-NP
O	164	165	-	-	HYPH	I-NP
O	165	177	inflammatory	inflammatory	JJ	I-NP
O	178	185	peptide	peptide	NN	I-NP
O	185	186	,	,	,	O
O	187	189	LL	LL	NN	B-NP
O	189	190	-	-	HYPH	O
O	190	192	37	37	CD	B-NP
O	192	193	,	,	,	O
O	194	197	and	and	CC	O
O	198	201	its	its	PRP$	B-NP
O	202	205	pro	pro	AFX	I-NP
O	205	206	-	-	HYPH	I-NP
O	206	210	form	form	NN	I-NP
O	210	211	,	,	,	O
O	212	217	human	human	JJ	B-NP
O	218	226	cationic	cationic	JJ	I-NP
O	227	240	antimicrobial	antimicrobial	JJ	I-NP
O	241	248	protein	protein	NN	I-NP
O	249	251	18	18	CD	I-NP
O	252	253	(	(	(	O
O	253	257	hCAP	hCAP	NN	B-NP
O	257	258	-	-	HYPH	O
O	258	260	18	18	CD	B-NP
O	260	261	)	)	)	O
O	261	262	,	,	,	O
O	263	265	in	in	IN	B-PP
B-Cancer	266	272	cancer	cancer	NN	B-NP
O	273	284	development	development	NN	I-NP
O	285	288	and	and	CC	O
O	289	300	progression	progression	NN	B-NP
O	301	303	is	be	VBZ	B-VP
O	304	310	poorly	poorly	RB	I-VP
O	311	321	understood	understand	VBN	I-VP
O	321	322	.	.	.	O

O	323	325	In	In	IN	B-PP
O	326	333	damaged	damage	VBN	B-NP
O	334	337	and	and	CC	I-NP
O	338	346	inflamed	inflamed	JJ	I-NP
B-Tissue	347	353	tissue	tissue	NN	I-NP
O	353	354	,	,	,	O
O	355	357	LL	LL	NN	B-NP
O	357	358	-	-	HYPH	O
O	358	360	37	37	CD	B-NP
O	361	370	functions	function	NNS	I-NP
O	371	373	as	as	IN	B-PP
O	374	375	a	a	DT	B-NP
O	376	391	chemoattractant	chemoattractant	NN	I-NP
O	391	392	,	,	,	O
O	393	400	mitogen	mitogen	NN	B-NP
O	401	404	and	and	CC	O
O	405	408	pro	pro	AFX	O
O	408	409	-	-	HYPH	O
O	409	419	angiogenic	angiogenic	JJ	B-NP
O	420	426	factor	factor	NN	I-NP
O	427	437	suggesting	suggest	VBG	B-VP
O	438	442	that	that	IN	B-SBAR
O	443	446	the	the	DT	B-NP
O	447	454	peptide	peptide	NN	I-NP
O	455	458	may	may	MD	B-VP
O	459	469	potentiate	potentiate	VB	I-VP
B-Cancer	470	475	tumor	tumor	NN	B-NP
O	476	487	progression	progression	NN	I-NP
O	487	488	.	.	.	O

O	489	492	The	The	DT	B-NP
O	493	496	aim	aim	NN	I-NP
O	497	499	of	of	IN	B-PP
O	500	504	this	this	DT	B-NP
O	505	510	study	study	NN	I-NP
O	511	514	was	be	VBD	B-VP
O	515	517	to	to	TO	B-VP
O	518	530	characterize	characterize	VB	I-VP
O	531	534	the	the	DT	B-NP
O	535	547	distribution	distribution	NN	I-NP
O	548	550	of	of	IN	B-PP
O	551	555	hCAP	hCAP	NN	B-NP
O	555	556	-	-	HYPH	B-NP
O	556	558	18	18	CD	I-NP
O	558	559	/	/	SYM	I-NP
O	559	561	LL	LL	NN	I-NP
O	561	562	-	-	SYM	B-NP
O	562	564	37	37	CD	B-NP
O	565	567	in	in	IN	B-PP
O	568	574	normal	normal	JJ	B-NP
O	575	578	and	and	CC	I-NP
B-Cancer	579	588	cancerous	cancerous	JJ	I-NP
I-Cancer	589	596	ovarian	ovarian	JJ	I-NP
I-Cancer	597	603	tissue	tissue	NN	I-NP
O	604	607	and	and	CC	O
O	608	610	to	to	TO	B-VP
O	611	618	examine	examine	VB	I-VP
O	619	622	the	the	DT	B-NP
O	623	630	effects	effect	NNS	I-NP
O	631	633	of	of	IN	B-PP
O	634	636	LL	LL	NN	B-NP
O	636	637	-	-	HYPH	B-NP
O	637	639	37	37	CD	I-NP
O	640	642	on	on	IN	B-PP
B-Cell	643	650	ovarian	ovarian	JJ	B-NP
I-Cell	651	657	cancer	cancer	NN	I-NP
I-Cell	658	663	cells	cell	NNS	I-NP
O	663	664	.	.	.	O

O	665	675	Expression	Expression	NN	B-NP
O	676	678	of	of	IN	B-PP
O	679	683	hCAP	hCAP	NN	B-NP
O	683	684	-	-	HYPH	B-NP
O	684	686	18	18	CD	I-NP
O	686	687	/	/	SYM	I-NP
O	687	689	LL	LL	NN	I-NP
O	689	690	-	-	SYM	O
O	690	692	37	37	CD	B-NP
O	693	696	was	be	VBD	B-VP
O	697	706	localized	localized	JJ	B-ADJP
O	707	709	to	to	TO	B-PP
B-Cell	710	716	immune	immune	JJ	B-NP
O	717	720	and	and	CC	I-NP
B-Cell	721	730	granulosa	granulosa	NN	I-NP
I-Cell	731	736	cells	cell	NNS	I-NP
O	737	739	of	of	IN	B-PP
O	740	746	normal	normal	JJ	B-NP
B-Tissue	747	754	ovarian	ovarian	JJ	I-NP
I-Tissue	755	761	tissue	tissue	NN	I-NP
O	761	762	.	.	.	O

O	763	765	By	By	IN	B-PP
O	766	774	contrast	contrast	NN	B-NP
O	774	775	,	,	,	O
B-Cancer	776	783	ovarian	ovarian	JJ	B-NP
I-Cancer	784	790	tumors	tumor	NNS	I-NP
O	791	800	displayed	display	VBD	B-VP
O	801	814	significantly	significantly	RB	B-NP
O	815	821	higher	high	JJR	I-NP
O	822	828	levels	level	NNS	I-NP
O	829	831	of	of	IN	B-PP
O	832	836	hCAP	hCAP	NN	B-NP
O	836	837	-	-	HYPH	B-NP
O	837	839	18	18	CD	I-NP
O	839	840	/	/	SYM	I-NP
O	840	842	LL	LL	NN	I-NP
O	842	843	-	-	SYM	O
O	843	845	37	37	CD	B-NP
O	846	851	where	where	WRB	B-ADVP
O	852	862	expression	expression	NN	B-NP
O	863	866	was	be	VBD	B-VP
O	867	875	observed	observe	VBN	I-VP
O	876	878	in	in	IN	B-PP
B-Cell	879	884	tumor	tumor	NN	B-NP
O	885	888	and	and	CC	O
B-Cell	889	896	stromal	stromal	JJ	B-NP
I-Cell	897	902	cells	cell	NNS	I-NP
O	902	903	.	.	.	O

O	904	911	Protein	Protein	NN	B-NP
O	912	922	expression	expression	NN	I-NP
O	923	926	was	be	VBD	B-VP
O	927	940	statistically	statistically	RB	I-VP
O	941	949	compared	compare	VBN	I-VP
O	950	952	to	to	TO	B-PP
O	953	956	the	the	DT	B-NP
O	957	963	degree	degree	NN	I-NP
O	964	966	of	of	IN	B-PP
B-Cell	967	973	immune	immune	JJ	B-NP
I-Cell	974	978	cell	cell	NN	I-NP
O	979	991	infiltration	infiltration	NN	I-NP
O	992	995	and	and	CC	O
B-Tissue	996	1007	microvessel	microvessel	NN	B-NP
O	1008	1015	density	density	NN	I-NP
O	1016	1018	in	in	IN	B-PP
B-Cancer	1019	1029	epithelial	epithelial	JJ	B-NP
I-Cancer	1029	1030	-	-	HYPH	I-NP
I-Cancer	1030	1037	derived	derive	VBN	I-NP
I-Cancer	1038	1045	ovarian	ovarian	JJ	I-NP
I-Cancer	1046	1052	tumors	tumor	NNS	I-NP
O	1053	1056	and	and	CC	O
O	1057	1058	a	a	DT	B-NP
O	1059	1070	significant	significant	JJ	I-NP
O	1071	1082	correlation	correlation	NN	I-NP
O	1083	1086	was	be	VBD	B-VP
O	1087	1095	observed	observe	VBN	I-VP
O	1096	1099	for	for	IN	B-PP
O	1100	1104	both	both	DT	B-NP
O	1104	1105	.	.	.	O

O	1106	1108	It	It	PRP	B-NP
O	1109	1112	was	be	VBD	B-VP
O	1113	1125	demonstrated	demonstrate	VBN	I-VP
O	1126	1130	that	that	IN	B-SBAR
B-Organism_substance	1131	1138	ovarian	ovarian	JJ	B-NP
I-Organism_substance	1139	1144	tumor	tumor	NN	I-NP
I-Organism_substance	1145	1151	tissue	tissue	NN	I-NP
I-Organism_substance	1152	1159	lysates	lysate	NNS	I-NP
O	1160	1163	and	and	CC	O
B-Cell	1164	1171	ovarian	ovarian	JJ	B-NP
I-Cell	1172	1178	cancer	cancer	NN	I-NP
I-Cell	1179	1183	cell	cell	NN	I-NP
I-Cell	1184	1189	lines	line	NNS	I-NP
O	1190	1197	express	express	VBP	B-VP
O	1198	1202	hCAP	hCAP	NN	B-NP
O	1202	1203	-	-	HYPH	B-NP
O	1203	1205	18	18	CD	I-NP
O	1205	1206	/	/	SYM	I-NP
O	1206	1208	LL	LL	NN	I-NP
O	1208	1209	-	-	SYM	B-NP
O	1209	1211	37	37	CD	B-NP
O	1211	1212	.	.	.	O

O	1213	1222	Treatment	Treatment	NN	B-NP
O	1223	1225	of	of	IN	B-PP
B-Cell	1226	1233	ovarian	ovarian	JJ	B-NP
I-Cell	1234	1240	cancer	cancer	NN	I-NP
I-Cell	1241	1245	cell	cell	NN	I-NP
I-Cell	1246	1251	lines	line	NNS	I-NP
O	1252	1256	with	with	IN	B-PP
O	1257	1268	recombinant	recombinant	JJ	B-NP
O	1269	1271	LL	LL	NN	I-NP
O	1271	1272	-	-	HYPH	B-NP
O	1272	1274	37	37	CD	I-NP
O	1275	1285	stimulated	stimulated	JJ	I-NP
O	1286	1299	proliferation	proliferation	NN	I-NP
O	1299	1300	,	,	,	O
O	1301	1311	chemotaxis	chemotaxis	NN	B-NP
O	1311	1312	,	,	,	O
O	1313	1321	invasion	invasion	NN	B-NP
O	1322	1325	and	and	CC	O
O	1326	1332	matrix	matrix	NN	B-NP
O	1333	1350	metalloproteinase	metalloproteinase	NN	I-NP
O	1351	1361	expression	expression	NN	I-NP
O	1361	1362	.	.	.	O

O	1363	1368	These	These	DT	B-NP
O	1369	1373	data	datum	NNS	I-NP
O	1374	1385	demonstrate	demonstrate	VBP	B-VP
O	1386	1389	for	for	IN	B-PP
O	1390	1393	the	the	DT	B-NP
O	1394	1399	first	first	JJ	I-NP
O	1400	1404	time	time	NN	I-NP
O	1405	1409	that	that	IN	B-ADVP
O	1410	1414	hCAP	hCAP	NN	B-NP
O	1414	1415	-	-	HYPH	B-NP
O	1415	1417	18	18	CD	I-NP
O	1417	1418	/	/	SYM	I-NP
O	1418	1420	LL	LL	NN	I-NP
O	1420	1421	-	-	SYM	B-NP
O	1421	1423	37	37	CD	I-NP
O	1424	1426	is	be	VBZ	B-VP
O	1427	1440	significantly	significantly	RB	I-VP
O	1441	1454	overexpressed	overexpresse	VBN	I-VP
O	1455	1457	in	in	IN	B-PP
B-Cancer	1458	1465	ovarian	ovarian	JJ	B-NP
I-Cancer	1466	1472	tumors	tumor	NNS	I-NP
O	1473	1476	and	and	CC	O
O	1477	1484	suggest	suggest	VBP	B-VP
O	1485	1487	LL	LL	NN	B-NP
O	1487	1488	-	-	HYPH	O
O	1488	1490	37	37	CD	B-NP
O	1491	1494	may	may	MD	B-VP
O	1495	1505	contribute	contribute	VB	I-VP
O	1506	1508	to	to	TO	B-PP
B-Organ	1509	1516	ovarian	ovarian	JJ	B-NP
O	1517	1530	tumorigenesis	tumorigenesis	NN	I-NP
O	1531	1538	through	through	IN	B-PP
O	1539	1545	direct	direct	JJ	B-NP
O	1546	1557	stimulation	stimulation	NN	I-NP
O	1558	1560	of	of	IN	B-PP
B-Cell	1561	1566	tumor	tumor	NN	B-NP
I-Cell	1567	1572	cells	cell	NNS	I-NP
O	1572	1573	,	,	,	O
O	1574	1584	initiation	initiation	NN	B-NP
O	1585	1587	of	of	IN	B-PP
O	1588	1600	angiogenesis	angiogenesis	NN	B-NP
O	1601	1604	and	and	CC	I-NP
O	1605	1616	recruitment	recruitment	NN	I-NP
O	1617	1619	of	of	IN	B-PP
B-Cell	1620	1626	immune	immune	JJ	B-NP
I-Cell	1627	1632	cells	cell	NNS	I-NP
O	1632	1633	.	.	.	O

O	1634	1639	These	These	DT	B-NP
O	1640	1644	data	datum	NNS	I-NP
O	1645	1652	provide	provide	VBP	B-VP
O	1653	1660	further	further	JJ	B-NP
O	1661	1669	evidence	evidence	NN	I-NP
O	1670	1672	of	of	IN	B-PP
O	1673	1676	the	the	DT	B-NP
O	1677	1685	existing	exist	VBG	I-NP
O	1686	1698	relationship	relationship	NN	I-NP
O	1699	1706	between	between	IN	B-PP
O	1707	1710	pro	pro	AFX	B-NP
O	1710	1711	-	-	HYPH	I-NP
O	1711	1723	inflammatory	inflammatory	JJ	I-NP
O	1724	1733	molecules	molecule	NNS	I-NP
O	1734	1737	and	and	CC	O
B-Cancer	1738	1745	ovarian	ovarian	JJ	B-NP
I-Cancer	1746	1752	cancer	cancer	NN	I-NP
O	1753	1764	progression	progression	NN	I-NP
O	1764	1765	.	.	.	O

